In 1964, when the first seven physicians who founded ASCO met, I doubt they imagined what a successful Society they were forming. At that time, cancer treatments were just beginning to have some early successes with a few cytotoxic therapies, new radiation modalities, and improved surgical techniques.
Over the ensuing 50 years, the advancements in cancer care and research have been extraordinary. Fast forward to 2015 when ASCO has nearly40,000 members from over 120 countries, and the ASCO Annual Meeting in Chicago has in excess of 37,000 attendees. Our founders would be so proud of what ASCO provides in education, information, support, mentorship, and research funding.
I am very honored to be the 52nd President of ASCO and to represent our membership. I chose the theme of “Collective Wisdom: Patient-Centered Care and Research” to represent the importance of the multimodality care that is necessary for our patients. As this figure demonstrates (Fig. 1), the patient is at the center of a very complex system trying to assist him/her through their journey of cancer care.
Today, the ability to deliver the optimum care to our patients is becoming ever-more challenging. We have so many more options for treatment than in years past, but the ability to provide the therapies is sometimes met with obstacles. The availability and affordability of the new therapies varies by country and health care system. As the health care systems change from a reimbursement-based system to a value-based system, we must continue to modify our models of care. Clinical research must also include a component of cost-effectiveness in studies to help physicians and patients make informed decisions. However, we must always remember that the patient is the center of the circle, and the goal is to assist them in informed decision-making.
The multidisciplinary aspects of cancer care and research continue to be very important with advances in the understanding of the biology and genomics of different malignancies. This emphasizes the importance of education and communication between the team members on a regular basis.
In addition, as we make improvements in cancer care, there will be many more cancer survivors who will need medical and supportive care to get beyond the cancer treatment and back to a normal life. Much of this care will be carried out by a medical team that by necessity is much broader than the oncology team.
All of the improvements made in cancer care over the last decades depended on the clinical and research data gathered and analyzed to improve future care. To continue to make advances, we must find ways to streamline and use efficiently the data gathered from all patients to inform our treatment patterns. Clinical trials will need to be optimized and a broader range of data on all patients will need to be obtained and analyzed.
Over the next year, the issues that I, and the ASCO leadership, will be addressing include value-based care models, workforce-shortage issues, clinical cancer research best practices and optimization, big data analysis through CancerLinQ™, quality measures through QOPI®, and improvement in care delivery globally. As medical professionals and as a Society, we must all continue to evolve and transform cancer care and research with each new discovery.
We can only hope that 50 years from now, future medical professionals who care for patients with cancer and who perform cancer research can look back and thank us for the pioneering aspects of treatments that were developed in our era.
Mark Allen O'Rourke, MD
Jun, 08 2015 10:58 PM
"Data gathered from all patients" needs to include individual geriatric assessments, individual priorities, and individual preferences. Thank you, Dr. Vose, for your leadership.
Carl Freter, MD, PhD
Jun, 12 2015 12:19 PM
I am very pleased to see a vision that I believe is responsive to and inclusive of the array of issues facing us in improving cancer care for our patients presently, and for coming generations. We live in a time of great challenge as well as great opportunity, and I am thankful for your leadership.
Carl E Freter, MD, PhD, FACP,
Professor and Director, Division of Hematology/Oncology/Stem cell therapies; Associate Director, Saint Louis University Cancer Center.
Julie Vose, MD, MBA, FASCO
Jun, 15 2015 9:37 PM
Thank you for your comments! I look forward to my year as ASCO President and trying to make a difference.